PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22842456-0	2012	Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562.	Imatinib Mesylate	52-60	microRNA 144	Homo sapiens	12-19	
22842456-3	2012	In this study, we first found that c-myc expression is upregulated in imatinib resistant K562R cells, which in turn enhances the expression of miR-144/451.	Imatinib Mesylate	70-78	microRNA 144	Homo sapiens	143-150	
22842456-4	2012	Knockdown of c-myc or restoration of miR-144/451 in the K562R cells sensitizes K562R cells to imatinib therapy.	Imatinib Mesylate	94-102	microRNA 144	Homo sapiens	37-44	
22842456-5	2012	Our study here reveals an regulatory pathway between myc and miR-144/451 and highlights that targeting either myc or miR-144/451 might be valuable for eliminating the imatinib resistant CML cells.	Imatinib Mesylate	167-175	microRNA 144	Homo sapiens	61-68	
22842456-5	2012	Our study here reveals an regulatory pathway between myc and miR-144/451 and highlights that targeting either myc or miR-144/451 might be valuable for eliminating the imatinib resistant CML cells.	Imatinib Mesylate	167-175	microRNA 144	Homo sapiens	117-124